Can a common antipsychotic keep cannabis users out of the ER?
NCT ID NCT07726069
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This trial tests whether giving patients a prescription for haloperidol to use as needed at home can help control symptoms of cannabinoid hyperemesis syndrome — a condition marked by severe nausea, vomiting, and abdominal pain from heavy cannabis use. The goal is to see if having the medication available reduces the number of return visits to the emergency department. One hundred adults diagnosed with the syndrome who are safe to go home will receive the prescription and be followed for symptom improvement and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- haloperidol, an antipsychotic medication taken as needed for symptom control
- What this could lead to
- If it works, this could give patients a way to manage cannabinoid hyperemesis syndrome at home and reduce repeat emergency visits.
- What could go wrong
- This is a very early-phase trial with only 100 participants. Haloperidol can cause side effects like drowsiness, movement problems, or heart rhythm changes, and it may not prevent return ER visits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANNABINOID HYPEREMESIS SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Illinois Hospital
Chicago, Illinois, 60612, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.